OPEN END TURBO OPTIONSSCHEIN SHORT - NOVO-NORDISK B | Real-time BOERSE MUENCHEN 10:25:44 2024-05-28 am EDT | ||
| 4.937 EUR | +1.98% |
|
| Current month | -4.70% | ||
| 1 month | -9.68% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-05-28 | 4.937 | +1.98% |
| 24-05-27 | 4.841 | +1.96% |
| 24-05-24 | 4.748 | +2.00% |
| 24-05-23 | 4.655 | -5.00% |
| 24-05-22 | 4.9 | +2.08% |
Real-time BOERSE MUENCHEN
Last update May 28, 2024 at 10:25 am EDT
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | NOVO NORDISK A/S |
| Issuer | Goldman Sachs |
| WKN | GG05G6 |
| ISIN | DE000GG05G62 |
| Date issued | 2023-11-23 |
| Strike | 1,282 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 7.93 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 8.664 € |
|---|---|
| Lowest since issue | 4.597 € |
| Spread | 0.05 € |
| Spread % | 1.01% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
915.7
DKK
Average target price
909.2
DKK
Spread / Average Target
-0.71%
- Stock Market
- Certificates
- Certificat
